Transcription profiling of topoisomerase I inhibitor irinotecan (CPT-11) sensitive, resistant, and reverted human neuroblastomas
Ontology highlight
ABSTRACT: We have established a neuroblastoma model resistant in vivo to the topoisomerase I inhibitor irinotecan (CPT-11, Camptothecin-11, CAMPTOSAR®) in order to study resistance to these agents acquired in a therapeutic setting. Common mechanisms of resistance were not involved in this model and we thus explored the gene expression signature associated with resistance by comparing the transcriptomes of sensitive, resistant, and reverted tumours using high-throughput DNA microarrays.
ORGANISM(S): Homo sapiens
SUBMITTER: Hugues Ripoche
PROVIDER: E-TABM-211 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA